Market data not licensed for redistribution.
ImmuneOncia Therapeutics
424870 ยท KOSDAQ ยท R&D in Natural Sciences & Engineering
Close
Source: Financial Services Commission stock price data (data.go.kr), updated once a day.
Daily price, 1 year
Key statistics
Market cap (KRW bn)โ
PERโ
PBRโ
ROE %-29.2
Debt ratio % (liabilities / equity)5
Revenue TTM (KRW bn)0.0
Op. profit TTM (KRW bn)-30.2
Dividend yield %โ
Basis: market cap at โฆ; equity = total equity (consolidated if available) at 2026.06.30; net income = trailing 12 months to 2026.06.30 (separate). PER is not shown when TTM net income is negative.
Upcoming risk events
Next 90 days for this company, plus macro events tagged with this ticker or its sector. Not a recommendation.
No scheduled risk events found (last checked 2026-10-30 19:40 KST).
Annual results (KRW bn)
| 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Revenue | โ | โ | โ | โ | 0.1 |
| Operating profit | โ | โ | โ | โ | -28.0 |
| Net income | โ | โ | โ | โ | -27.4 |
Quarterly results (KRW bn, 3 months)
| 2025Q1 | 2025Q2 | 2025Q3 | 2025Q4 | 2026Q1 | 2026Q2 | |
|---|---|---|---|---|---|---|
| Revenue | โ | 0.1 | โ | 0.0 | 0.0 | 0.0 |
| Operating profit | โ | -3.3 | -10.6 | -9.6 | -5.8 | -4.3 |
| Net income | โ | -3.1 | -10.4 | -9.4 | -5.6 | -3.9 |
Largest shareholder
As of the 2025 annual report: (์ฃผ)์ ํ์ํ and related parties hold 65.93% of common shares.
Recent disclosures
| Date | Filing | Summary | |
|---|---|---|---|
| 2026-10-28 | Unfaithful-disclosure notice ๋ถ์ฑ์ค๊ณต์๋ฒ์ธ์ง์ ์๊ณ (๊ณต์๋ถ์ดํ 2๊ฑด) | DART original | |
| 2026-10-15 | IR event ๊ธฐ์ ์ค๋ช ํ(IR)๊ฐ์ต | DART original | |
| 2026-09-14 | Clinical trial / regulatory approval ํฌ์ํ๋จ๊ด๋ จ์ฃผ์๊ฒฝ์์ฌํญ(์์์ํ๊ณํ๋ณ๊ฒฝ์น์ธ) (IMC-002์ ์ 1์ ์์์ํ๊ณํ ๋ณ๊ฒฝ์น์ธ) | DART original | |
| 2026-09-14 | Clinical trial / regulatory approval ํฌ์ํ๋จ๊ด๋ จ์ฃผ์๊ฒฝ์์ฌํญ(์์์ํ๊ณํ๋ณ๊ฒฝ์น์ธ์ ์ฒญ) (IMC-002์ ์ 1์ ์์์ํ๊ณํ ๋ณ๊ฒฝ์น์ธ์ ์ฒญ) | DART original | |
| 2026-08-14 | Periodic report (annual/half/quarterly) ๋ฐ๊ธฐ๋ณด๊ณ ์ (2026.06) | DART original | |
| 2026-07-28 | Insider / major-holder ownership report ์์ใ์ฃผ์์ฃผ์ฃผํน์ ์ฆ๊ถ๋ฑ์์ ์ํฉ๋ณด๊ณ ์ | DART original | |
| 2026-05-28 | Insider / major-holder ownership report ์์ใ์ฃผ์์ฃผ์ฃผํน์ ์ฆ๊ถ๋ฑ์์ ์ํฉ๋ณด๊ณ ์ | DART original | |
| 2026-05-27 | Insider / major-holder ownership report ์ฃผ์๋ฑ์๋๋๋ณด์ ์ํฉ๋ณด๊ณ ์(์ผ๋ฐ) | DART original | |
| 2026-05-27 | Insider / major-holder ownership report ์์ใ์ฃผ์์ฃผ์ฃผํน์ ์ฆ๊ถ๋ฑ์์ ์ํฉ๋ณด๊ณ ์ | DART original | |
| 2026-05-21 | Securities registration / prospectus ์ฆ๊ถ๋ฐํ๊ฒฐ๊ณผ(์์จ๊ณต์) | DART original | |
| 2026-05-21 | Securities registration / prospectus ์ฆ๊ถ๋ฐํ์ค์ ๋ณด๊ณ ์ | DART original | |
| 2026-05-15 | Securities registration / prospectus ์ ์์ฆ์๋๋์ฃผ์๊ด๋ จ์ฌ์ฑ๋ฑ์์ฒญ์ฝ๊ฒฐ๊ณผ(์์จ๊ณต์) | DART original |
Past material filings and price reaction (market-adjusted)
| Date | Filing type | On the news (vs. market) | Next day (vs. market) | 20 days (vs. market) |
|---|---|---|---|---|
| 2026-09-14 | Clinical trial / regulatory approval | +30.0% | -0.7% | โ |
| 2026-02-06 | Rights offering (paid-in capital increase) | -17.4% | +4.8% | +1.0% |
| 2026-02-06 | Revenue/profit change >=30% (15% large caps) | -17.4% | +4.8% | +1.0% |
| 2025-11-28 | Clarification of rumor / inquiry | -3.8% | -8.1% | +32.7% |
| 2025-11-27 | Clarification of rumor / inquiry | -1.0% | -2.8% | +28.4% |
For information only, not investment advice. Data may be delayed or inaccurate. Full disclaimer โ Data: OpenDART (FSS), stock prices: official previous-day close from the Financial Services Commission (data.go.kr) and FinanceData/marcap history, index data via FinanceDataReader, FX: ECB reference rates, crypto data from Upbit, Bithumb and Binance public APIs.
Market data not licensed for redistribution.
ยฉ Crypvu ยท Crypto market view
Market data not licensed for redistribution.
ยฉ Crypvu ยท Crypto market view